[
  {
    "ts": null,
    "headline": "Pharma sector outlook as Trump's drug tariff deadline looms",
    "summary": "Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca’s (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=70ca672e6fd4e363c7c1b4bb9ea9d687b46f09a425e0b23a0b520aada557cd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753214713,
      "headline": "Pharma sector outlook as Trump's drug tariff deadline looms",
      "id": 136038196,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks are in focus as President Trump's drug tariff deadline looms. Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination with Josh Lipton to discuss the impact that pharmaceutical tariffs could have on the sector, Astrazeneca’s (AZN) $50 billion commitment to US investments, and how the industry is navigating pressure from Washington and shifting global demand. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=70ca672e6fd4e363c7c1b4bb9ea9d687b46f09a425e0b23a0b520aada557cd1e"
    }
  },
  {
    "ts": null,
    "headline": "Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock",
    "summary": "Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.",
    "url": "https://finnhub.io/api/news?id=a621e3ed253e0b5c49a3f5d10a43b12acafb6c2cdf811b51032f273bcda81c20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753205380,
      "headline": "Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock",
      "id": 136033465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma treatment.",
      "url": "https://finnhub.io/api/news?id=a621e3ed253e0b5c49a3f5d10a43b12acafb6c2cdf811b51032f273bcda81c20"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Declares Fourth Dividend US$0.81; Keytruda Gains Approval for Cervical Cancer",
    "summary": "Merck (MRK) recently announced a dividend of $0.81 per share for Q4 2025 and gained Health Canada approval for KEYTRUDA® in treating cervical cancer. These developments align with Merck’s ongoing strategy to enhance shareholder value and expand its therapeutic offerings. Despite these positive milestones, Merck's stock price remained flat over the last quarter. This aligns with broader market behavior, as the S&P 500 and Nasdaq recently retreated from record highs. While the company's...",
    "url": "https://finnhub.io/api/news?id=25ef0809cee6a1f8a25a62144ac73d0fcef9a6253f62fd2116017814563fca20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753205270,
      "headline": "Merck (MRK) Declares Fourth Dividend US$0.81; Keytruda Gains Approval for Cervical Cancer",
      "id": 136033466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently announced a dividend of $0.81 per share for Q4 2025 and gained Health Canada approval for KEYTRUDA® in treating cervical cancer. These developments align with Merck’s ongoing strategy to enhance shareholder value and expand its therapeutic offerings. Despite these positive milestones, Merck's stock price remained flat over the last quarter. This aligns with broader market behavior, as the S&P 500 and Nasdaq recently retreated from record highs. While the company's...",
      "url": "https://finnhub.io/api/news?id=25ef0809cee6a1f8a25a62144ac73d0fcef9a6253f62fd2116017814563fca20"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=e7f4353a81157e5b2cf337e840a21b4a3c67ee133c8d586780e3482167d40e2b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753202040,
      "headline": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "id": 136042445,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=e7f4353a81157e5b2cf337e840a21b4a3c67ee133c8d586780e3482167d40e2b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Fourth-Quarter 2025 Dividend",
    "summary": "RAHWAY, N.J., July 22, 2025--Merck Announces Fourth-Quarter 2025 Dividend",
    "url": "https://finnhub.io/api/news?id=e2070471655f88ea86af8b88ef29e7e6e22db4274a6b64cf0c3eb0b125d0a69e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753199580,
      "headline": "Merck Announces Fourth-Quarter 2025 Dividend",
      "id": 136033467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., July 22, 2025--Merck Announces Fourth-Quarter 2025 Dividend",
      "url": "https://finnhub.io/api/news?id=e2070471655f88ea86af8b88ef29e7e6e22db4274a6b64cf0c3eb0b125d0a69e"
    }
  },
  {
    "ts": null,
    "headline": "7 MM Pulmonary Arterial Hypertension Market Drug Forecast and Market Analysis 2025 | A $9.34 Billion Market by 2034 - Winrevair is Reshaping the Treatment Landscape Following Its Commercial Launch",
    "summary": "The Pulmonary Arterial Hypertension (PAH) market in 7MM (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $7.65 billion in 2024 to $9.35 billion by 2034, driven by rising cases, combination therapies, and new drug launches like Merck's Winrevair. The US dominates with 76.3% market share.Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The \"Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034\" report has been added to ResearchAndMarkets.com's off",
    "url": "https://finnhub.io/api/news?id=941ed09c667794e9f2da52cd32341f6e9c069633ab1743787b8f576de43492d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753195320,
      "headline": "7 MM Pulmonary Arterial Hypertension Market Drug Forecast and Market Analysis 2025 | A $9.34 Billion Market by 2034 - Winrevair is Reshaping the Treatment Landscape Following Its Commercial Launch",
      "id": 136033468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Pulmonary Arterial Hypertension (PAH) market in 7MM (US, France, Germany, Italy, Spain, UK, Japan) is projected to grow from $7.65 billion in 2024 to $9.35 billion by 2034, driven by rising cases, combination therapies, and new drug launches like Merck's Winrevair. The US dominates with 76.3% market share.Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The \"Pulmonary Arterial Hypertension: Seven-Market Drug Forecast and Market Analysis to 2034\" report has been added to ResearchAndMarkets.com's off",
      "url": "https://finnhub.io/api/news?id=941ed09c667794e9f2da52cd32341f6e9c069633ab1743787b8f576de43492d6"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for",
    "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=fc2047ed22dc46a200b5f4d60725f4e958780100613218a1bcd72f489a921b56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753192810,
      "headline": "Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for",
      "id": 136033469,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=fc2047ed22dc46a200b5f4d60725f4e958780100613218a1bcd72f489a921b56"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Biomarkers Market Forecast 2025-2034 Featuring Analysis of Roche, Merck, Thermo Fisher Scientific, QIAGEN and Other Industry Leaders",
    "summary": "Key growth drivers include rising demands for high-sensitivity diagnostics and personalized medicine, advancements in genomics, proteomics, and AI-driven innovations, and notable partnerships enhancing biomarker assay development and precision healthcare across regions. U.S. Biomarkers Market U.S. Biomarkers Market Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The \"United States Biomarkers Market Report 2025-2034\" has been added to ResearchAndMarkets.com's offering. The report details market valuati",
    "url": "https://finnhub.io/api/news?id=2a7a16f55639eb955e75f7de288a7e9f7c71f636aba7b3b22c549230cb23aaf5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753191120,
      "headline": "U.S. Biomarkers Market Forecast 2025-2034 Featuring Analysis of Roche, Merck, Thermo Fisher Scientific, QIAGEN and Other Industry Leaders",
      "id": 136031429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Key growth drivers include rising demands for high-sensitivity diagnostics and personalized medicine, advancements in genomics, proteomics, and AI-driven innovations, and notable partnerships enhancing biomarker assay development and precision healthcare across regions. U.S. Biomarkers Market U.S. Biomarkers Market Dublin, July 22, 2025 (GLOBE NEWSWIRE) -- The \"United States Biomarkers Market Report 2025-2034\" has been added to ResearchAndMarkets.com's offering. The report details market valuati",
      "url": "https://finnhub.io/api/news?id=2a7a16f55639eb955e75f7de288a7e9f7c71f636aba7b3b22c549230cb23aaf5"
    }
  },
  {
    "ts": null,
    "headline": "GreensKeeper Value Fund Q2 2025 Letter",
    "summary": "GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when others chase hype.",
    "url": "https://finnhub.io/api/news?id=088040f4d5da88e72b06ff2ba21db4bb9a524f27a220fae8670d4b6eec1939f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753177800,
      "headline": "GreensKeeper Value Fund Q2 2025 Letter",
      "id": 136031607,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217643493/image_2217643493.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GreensKeeper stays cautious amid frothy markets, betting on long-term value. Learn how disciplined investing can thrive when others chase hype.",
      "url": "https://finnhub.io/api/news?id=088040f4d5da88e72b06ff2ba21db4bb9a524f27a220fae8670d4b6eec1939f4"
    }
  }
]